This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Novo Nordisk has partnered with Amalgam Rx, a leader in digital therapeutics, to provide Dose Check globally. Dose Check is a mobile basal insulin titration app for people with type 2 diabetes using Novo Nordisk basal insulin treatment. It may be an aid to guide patients to achieve their optimal dose, based on a personalised titration algorithm defined by their healthcare professional. Dose Check helps healthcare professionals to extend their clinical advice, with the app providing daily support to ensure people make a confident start on insulin therapy.
 

Dose Check is available by prescription only for use by adults aged 21 and above who have type 2 diabetes and their healthcare providers to titrate basal insulin and medications that combine basal insulin and GLP-1 receptor agonists. It is not intended to replace the care and management provided by a healthcare professional trained in the management of diabetes.

Dose Check is not for use by patients with type 2 diabetes who are also using prandial insulin or patients with type 1 diabetes, gestational diabetes, or patients using an insulin pump.

Digital Health Solutions

 

With our digital therapeutic technologies and device innovations, we aim to improve the health and well-being of people living with diabetes around the world.

Smart pens. Smarter Care

 

The smart insulin pens NovoPen® 6 & NovoPen Echo® Plus are designed to improve insulin dose recording. This may help HCPs to have informed discussions with diabetes patients based on individual injection data.1-3

dose check

 

Designed to simplify initiation and titration of basal insulin. Discover how Dose Check can help you and your patients with daily insulin dose guidance.

1.

NovoPen® 6 & NovoPen Echo® Plus Design Specification / Verification Report (Data on File).

2.

Klonoff DC et al. JDiabetes SciTechnol. 2018;12(3):551-553.

3.

Peter Adolfsson et al. Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen. DIABETES TECHNOLOGY & THERAPEUTICS Volume 22, Number 10, 2020

4.

Data on file: Technical Specification Document & Device Description (DDSC-1) Amalgam Guide.



NovoPen® 6 and NovoPen Echo® Plus are CE-marked medical devices. Notified body 0123.
NovoPen® 6 and NovoPen Echo® Plus are certified against the EU Medical Device Directive (MDD) 93/42/EEC.
NovoPen® 6 and NovoPen Echo® Plus are available in a number of countries with additional launches planned in the near future. Timeframes will vary according to device, insulin brand and unique market regulations.

Dose Check is CE marked. Notified body 2868. Dose Check is certified against the EU Medical Device Regulations (MDR) 2017/745.
Manufacturer: Amalgam Rx, Inc. 1007 N. Orange St, Ste. 400, Wilmington, DE 19801, USA
Authorized Representative: Medical Device Safety Service GmbH, Schiffgraben 41, 30175 Hannover, Germany.
Dose Check is available in a number of countries and additional launches are planned in the near future. Timeframes will vary according to device, insulin brand and unique market regulations.
Dose guidance apps and the information contained in these materials are not intended as a substitute for professional medical advice.

The information contained on this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is suitable for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness, or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.

HQ24NP600020, June 2024